The PCSK9-REACT study demonstrated that elevated PCSK9 levels in acute coronary syndrome patients on dual antiplatelet therapy are associated with increased platelet reactivity, reduced antiplatelet efficacy and higher risk of major cardiovascular events [19]. Here, PCSK9 is linked to acute coronary syndrome.